Log In
Print
BCIQ
Print
Print this Print this
 

Bydureon (Exenatide once weekly)

Also known as: Byetta LAR, exenatide LAR (AC2993 LAR)

  Manage Alerts
Collapse Summary General Information
Company AstraZeneca plc
DescriptionLong-acting release (LAR) formulation of synthetic exendin-4
Molecular Target Glucagon-like peptide-1 receptor (GLP-1R) (GLP1R)
Mechanism of ActionGlucagon-like peptide-1 (GLP-1) receptor agonist
Therapeutic ModalityPeptide
Latest Stage of DevelopmentMarketed
Standard IndicationDiabetes
Indication DetailsTreat Type II diabetes; Treat Type II diabetes in combination with metformin, a sulfonylurea, a thiazolidinedione, metformin plus a sulfonylurea or metformin plus a thiazolidinedione
Regulatory Designation

Partner

Alkermes plc


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today